What is APLS's P/E ratio?

APELLIS PHARMACEUTICALS INC (APLS) currently trades at a P/E ratio of 22.41.

APELLIS PHARMACEUTICALS INC reports a Return on Equity (ROE) of 32.12%.

What is APLS's dividend yield?

APELLIS PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is APLS's Quality Score?

Our AI rates APLS's overall financial quality at 77 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy APLS?

Our AI Timing Score for APLS is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does APLS belong to?

APELLIS PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

APLS (NASDAQ) Stock Analysis | APELLIS PHARMACEUTICALS INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

APLS AI Analysis Summary

Our AI summary for APLS: APELLIS PHARMACEUTICALS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 22.41, ROE of 32.12%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

APLS

APELLIS PHARMACEUTICALS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 3.40

0.34 (11.27%) Day Change

Watchlist Portfolio Compare Chart

22.41

P/E

1.12

D/E

32.1%

ROE

12.3%

ROA

0.00%

Div Yield

-0.33

PEG

APELLIS PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.40 Price 0.34 (11.27%) Day Change	NEWS SCORE: 95

APLS, the overall quality is good ( Quality = 77) but the timing to buy is ...(Sign In to See)...

Loading chart...

77 QUALITY

Signal: OUTPERFORM

Signal Description: Company financial health is Good

Reason: Historical ROE is relatively low
ROA is too relatively low compare to ROE
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

55%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	2397
Magic Formula Rank by ROE	2397
Magic Formula Rank by ROIC	635
Price	3.40
PBV / Sector	12.66 / 5.20
Earning Per Share	0.09

PE / Sector	22.41 / 19.97
PEG or PE/Growth / Sector	-0.33 / 1.22
Average 1M Daily Value	439.627775000000
Average 1W Daily Value	421.271800000000

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	12.06 / 98.71
NPM Average (%) / Sector	-201.81 / -1,721.76
NPM Change Average (%) / Sector	41.55 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	12.31 / 27.02
ROA Average (%) / Sector	-32.16 / -368.17
ROA Change Average (%) / Sector	73.36 / 5,404.12 GREAT
ROE (%) / Sector	32.12 / 3.47 GREAT
ROE Average (%) / Sector	-140.82 / 6.51
ROE Change Average (%) / Sector	56.67 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:29
Symbol	APLS
Name	APELLIS PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	128.02 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	5,252.71 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Fifth Avenue, Waltham, MA, United States, 02451

Phone: 617 977 5700

Website: https://apellis.com

Employees: 733

Sector: Healthcare >> Biotechnology

Description: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.